Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Rezolute Inc.

In a report released on June 2, Matt Hewitt from Craig-Hallum maintained a Hold rating on Rezolute. The company’s shares closed yesterday at $4.00....

Craig-Hallum Keeps Their Hold Rating on Rezolute (RZLT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rezolute (RZLT) and Relay Therapeutics (RLAY) with b...

Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aveanna Healthcare Holdings (AVAH) and Rezolute (RZL...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RZLT	$5.02	+4.80%	2.81M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RZLT	$5.02	+4.8%	2.81M
3
4
5
6

RZLT

RZLT

Dividend Overview

Get Rezolute Inc. Data in Excel

Get Rezolute Inc. Data in Excel